Tibsovo (ivosidenib) vs Truseltiq (infigratinib)
Tibsovo (ivosidenib) vs Truseltiq (infigratinib)
Tibsovo (ivosidenib) is an oral medication specifically approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Truseltiq (infigratinib) is also an oral medication, but it is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. The choice between Tibsovo and Truseltiq would depend on the specific type of cancer a patient has and the presence of the respective genetic mutations; therefore, genetic testing and a discussion with a healthcare provider are essential to determine the appropriate treatment option.
Difference between Tibsovo and Truseltiq
| Metric | Tibsovo (ivosidenib) | Truseltiq (infigratinib) |
|---|---|---|
| Generic name | Ivosidenib | Infigratinib |
| Indications | Acute myeloid leukemia (AML) with a specific genetic mutation (IDH1) | Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a specific genetic mutation (FGFR2) |
| Mechanism of action | Inhibits the mutant IDH1 enzyme, leading to a reduction in the oncometabolite 2-hydroxyglutarate (2-HG) levels | FGFR kinase inhibitor that blocks FGFR signaling and decreases cell proliferation |
| Brand names | Tibsovo | Truseltiq |
| Administrative route | Oral | Oral |
| Side effects | Fatigue, joint pain, diarrhea, dyspnea, edema, nausea, mucositis, QT interval prolongation, rash, fever, cough, constipation | Hyperphosphatemia, stomatitis, fatigue, alopecia, diarrhea, dry mouth, dysgeusia, nail toxicity, musculoskeletal pain, dry skin, decreased appetite, nausea, vomiting, constipation |
| Contraindications | Known hypersensitivity to ivosidenib or any of its excipients | Known hypersensitivity to infigratinib or any of its excipients |
| Drug class | Isocitrate dehydrogenase-1 (IDH1) inhibitor | Fibroblast growth factor receptor (FGFR) inhibitor |
| Manufacturer | Agios Pharmaceuticals, Inc. | QED Therapeutics, Inc. |
Efficacy
Tibsovo (Ivosidenib) Efficacy in Bile Duct Cancer
Tibsovo, the brand name for ivosidenib, is a targeted therapy that has shown efficacy in the treatment of bile duct cancer, also known as cholangiocarcinoma, in patients with a specific genetic mutation. It is designed to inhibit the mutated form of the isocitrate dehydrogenase 1 (IDH1) enzyme, which is found in some patients with this type of cancer. The presence of the IDH1 mutation can be identified through molecular testing, and Tibsovo is intended for those who test positive for this mutation.
In clinical trials, Tibsovo demonstrated a significant impact on patients with IDH1-mutated cholangiocarcinoma. The response rate and duration of response were key measures of its efficacy. Patients treated with Tibsovo experienced a reduction in tumor size, with some achieving partial or complete responses. The median duration of response also suggested a potential for long-term benefit in a subset of patients.
Truseltiq (Infigratinib) Efficacy in Bile Duct Cancer
Truseltiq, known generically as infigratinib, is another targeted therapy that has been evaluated for its efficacy in treating bile duct cancer. Specifically, it targets abnormalities in the fibroblast growth factor receptor (FGFR) pathway, which can be altered in certain cancers, including cholangiocarcinoma. Truseltiq is used for patients who have a fusion or other rearrangement of FGFR2 (fibroblast growth factor receptor 2).
Clinical trials of Truseltiq have shown promising results for patients with FGFR2 fusion-positive cholangiocarcinoma. The drug has been associated with a meaningful response rate, indicating that a significant number of patients experienced tumor shrinkage. The duration of response and progression-free survival rates observed in the trials suggest that Truseltiq can provide a clinical benefit for patients with this specific genetic alteration in their bile duct cancer.
Regulatory Agency Approvals
Tibsovo
-
Food and Drug Administration (FDA), USA
Truseltiq
-
Food and Drug Administration (FDA), USA
Access Tibsovo or Truseltiq today
If Tibsovo or Truseltiq are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us